title: Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
authors.forename: E N M
authors.initials: EN
authors.lastname: Overkleeft
authors.forename: R
authors.initials: R
authors.lastname: Goldschmeding
authors.forename: F
authors.initials: F
authors.lastname: van Reekum
authors.forename: E E
authors.initials: EE
authors.lastname: Voest
authors.forename: H M W
authors.initials: HM
authors.lastname: Verheul
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib